Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.

Bone marrow transplantation - 1 May 2021

Maziarz Richard T, Levis Mark, Patnaik Mrinal M, Scott Bart L, Mohan Sanjay R, Deol Abhinav, Rowley Scott D, Kim Dennis D H, Hernandez Daniela, Rajkhowa Trivikram, Haines Kelly, Bonifacio Gaetano, Rine Patrice, Purkayastha Das, Fernandez Hugo F

Abstract excerpt

We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute myeloid leukemia (AML) harboring internal tandem duplication (ITD) in FLT3. Adults (aged 18-70 years) who received alloHSCT in first complete remission, had achieved hematologic recovery, and were transfusion independent were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Staurosporine

Share to Stem Cell Transplantation

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33288862
DOI: 10.1038/s41409-020-01153-1
PMCID: PMC8113057

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.PMID 33288862Read ↗

Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.Semantic proximity Read ↗

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.Semantic proximity Read ↗

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Semantic proximity Read ↗

Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis.Semantic proximity Read ↗

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.Semantic proximity Read ↗

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.Semantic proximity Read ↗

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.Semantic proximity Read ↗

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutationSemantic proximity Read ↗

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.Semantic proximity Read ↗

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsSemantic proximity Read ↗

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.